Target intelligence / Profile preview

Immunoglobulin heavy diversity 1-20 (IGHD1-20)

Target
IGHD1-20
Molecular classification
Other (Immunoglobulin gene segment)
01

Overview

IGHD1-20 is a diversity (D) gene segment in the immunoglobulin heavy chain locus (IGH) on chromosome 14. It encodes a short stretch of amino acids incorporated into the variable region of immunoglobulin heavy chains through somatic V(D)J recombination in developing B cells[1][3]. Multiple IGHD segments (including IGHD1-20) exist to increase the diversity of the antigen-binding sites of antibodies[1][3]. IGHD1-20 is not itself a receptor, enzyme, or drug target; instead, it is a genetic component required for the immense variability of immunoglobulins central to adaptive immunity[1][3].\n\nImmunoglobulin D segments such as IGHD1-20 are not directly expressed as proteins but are recombined during B cell development to produce variable regions of antibody heavy chains, together with V (variable) and J (joining) segments[1][3]. Entries like "IGHD1-20" do not represent druggable or functional protein targets, nor do they act as standalone disease biomarkers or receptors. In summary, IGHD1-20 is an immunoglobulin heavy chain diversity gene segment, not a therapeutic or functional target, and its inclusion as a target or receptor is a misclassification[1][3].

Other names
IGHD120IGHD1-20
02

Biological functions

Antibody diversity generationImmune response (by contribution to B cell receptor variability)
03

Disease associations

Other (germline or somatic defects in immunoglobulin gene rearrangement can contribute to immune deficiencies, but IGHD segments specifically are not common disease markers)

Beyond the preview

Go deeper on Immunoglobulin heavy diversity 1-20 (IGHD1-20).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy diversity 1-20 (IGHD1-20).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call